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Introduction: In 2006, the  Bacillus  Calmette–Guérin 
(BCG) vaccination policy in Finland changed from uni-
versal to selective. Aim: We assessed the impact of 
the policy change on tuberculosis (TB) morbidity in 
children under 5 years and epidemiological trends of 
paediatric TB in Finland. Methods: We conducted a 
nationwide, population-based, retrospective registry 
study of all newly diagnosed active TB cases younger 
than 15 years in Finland from 1995 to 2015 by linking 
data from the National Infectious Diseases Register, 
Finnish Care Register for Health Care, medical patient 
records and Finnish Population Information System. 
We compared the TB incidence rate ratio of under 5 
year-olds with universal and selective BCG vaccina-
tions with a Poisson log-linear model and analysed 
incidence trends among those younger than 15 years 
with a negative binomial model. Results: We identi-
fied 139 paediatric TB cases: 50 native (including 24 
second-generation migrants) and 89 foreign-born chil-
dren. The TB rate of under 5 year-olds remained stable 
after changing to selective BCG vaccination (incidence 
rate ratio (IRR): 1.3; 95% confidence interval (CI): 0.7–
2.3). TB rate in the native population under 15 years 
increased slightly (IRR = 1.06; 95% CI: 1.01–1.11).
Discussion: Paediatric TB cases in Finland were con-
centrated in families with migrant background from 
high-TB incidence countries. The native TB morbidity 
in under 5-year-olds did not increase after the BCG 
policy revision, suggesting that selective vaccinations 
can prevent TB in the most vulnerable age group in 
low-incidence settings. Second-generation migrants 
under 15 years in Finland with high TB risk are prob-
ably increasing.
Introduction
The World Health Organization (WHO) declared tuber-
culosis (TB) a global emergency more than 25 years 
ago. However, TB remains a major public health con-
cern and a leading cause of death from infection [1]. 
Young children are especially vulnerable to TB and 
severe disease [2]. In children, the incubation period 
from primary infection to disease is usually less than 
a year; childhood TB signals recent transmission and 
is a good indicator of the effectiveness of national TB 
control [3]. Nevertheless, epidemiological surveillance 
is generally focused on the adult population and the 
paediatric TB burden is often neglected.
Infant  Bacillus  Calmette–Guérin (BCG) vaccina-
tions prevent serious TB in children effectively [2,4]. 
Universal BCG vaccinations are still common in Europe 
[5]. The International Union Against Tuberculosis and 
Lung Disease and the WHO are, however, encouraging 
countries with declining TB incidence to consider dis-
continuation of universal BCG vaccinations [6,7]. The 
BCG policy revision is a major effort for national TB con-
trol programmes and understanding the implications is 
imperative [8]. The evidence of a threshold incidence 
for safe discontinuation of universal BCG is limited [8]. 
The initial studies evaluated BCG policy revisions that 
took place over 30 years ago and the landscape of TB 
in Europe has since changed drastically [9,10]. Recent 
nationwide population-based evaluations of universal 
BCG discontinuation are scarce, especially regarding 
BCG vaccination at birth, which is the WHO recom-
mendation and the most common universal policy in 
Europe [5,7].
Since 2001, the overall TB incidence in Finland has 
been lower than 10 per 100,000 population [11]. In 
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Figure 1
Flowchart of the record linkage from the data sources and exclusion of cases, paediatric tuberculosis, Finland, 1995–2015 
(n = 139)
61.2 % (85/139) in NIDR and Hilmo  
19 excluded 
     11 medical files not available 
      8 double-entered 
 
348 medical files assessed 
!
125 medical files assessed 
!
31 excluded 
     20 over 15 years of ageb 
       7 BCG  complication 
       2 only suspected TB 
       2 diagnosed abroad 
303 excluded  
     84 BCG  complication 
     38 latent TB 
     31 only suspected TB 
     27 diagnosed abroad 
     10 diagnosed before 1995 
      7 older than 15 yearsb 
     106 other c 
130 found from NIDR  
!
480 found from Hilmoa  
!
45 TB cases 
!
94 TB cases 
!
139 TB cases 
TB diagnosis under 16 
years of age,1995 2015 
 




     3 medical files not available 
     2 double-entered 
!
113 excluded 
     113 also in NIDR  
Population Register Centre !
Country of birth 
  100% (139/139) TB case 
  87.8% (122/139) mother 
  71.9% (100/139) father 
6.5 % (9/139) only in NIDR d  
!
BCG: Bacillus Calmette–Guérin; Hilmo: the Finnish Care Register for Health Care; NIDR: the National Infectious Diseases Register; TB: 
tuberculosis.
a Registered in the Hilmo with any diagnostic code for TB (ICD-9 010–018 or ICD-10 A15–19).
b Age at the time of first consultation for symptoms or of referral that led to the diagnosis.
c Patient without any TB suspicion in medical records (i.e. diagnostic code for TB used by mistake).
d Registered to the Hilmo with other than diagnostic code for TB (ICD-9 010–018 or ICD-10 A15–19).
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2006, the BCG policy changed from universal at birth 
to selective vaccinations of children at high TB risk 
only [12]. Consequently, the BCG coverage of infants 
dropped from more than 98% to an estimated 6–10% 
and the ensuing birth cohorts have grown up predomi-
nantly without BCG protection [13,14]. Simultaneously, 
immigration from countries with high TB incidence has 
caused a major transition of TB morbidity from the old 
indigenous to the young foreign-born population [11]. 
While TB cases among the native adult population have 
decreased, the migrant population and proportion of 
non-native TB cases among all cases in Finland have 
increased since 1995 from 2% to more than 5% and 
from 6% to more than 30%, respectively [11]. Although 
TB screening including a chest X-ray is recommended 
for migrants arriving from high-incidence countries, 
highly infectious pulmonary TB (pTB) cases are emerg-
ing among the working age population and exacerbat-
ing the risk of TB transmission [11,15].
TB surveillance in Finland relies on the National 
Infectious Diseases Register (NIDR) [11]. Until 2007, 
however, only bacteriologically or histologically con-
firmed cases were registered in the NIDR, while 
clinically diagnosed cases were not [11]. Achieving 
bacteriological confirmation from children is challeng-
ing and paediatric TB is often a clinical diagnosis [2]. 
Therefore, the incidence of paediatric TB in Finland has 
probably been under-reported.
We aimed to compare TB incidence rates in native chil-
dren under the age of 5 years born during the period 
with universal vs selective BCG vaccination policy and 
to assess the epidemiological trends of TB among 
native and foreign-born children under the age of 15 
years in Finland.
Methods
We conducted a nationwide, population-based, ret-
rospective study of registry data and medical patient 
records of all active TB cases in children under 15 years 
of age who were newly diagnosed in Finland between 
1995 and 2015.
As a part of national surveillance, it is statu-
tory for clinical microbiology laboratories to notify 
new  Mycobacterium tuberculosis  isolates and for 
physicians to notify clinically diagnosed or confirmed 
TB cases to the NIDR administrated by the National 
Institute for Health and Welfare (THL) [11]. Until 2006, 
the NIDR registered only bacteriologically or histologi-
cally confirmed cases. After adoption of the standard 
European Union TB case definition, clinically diag-
nosed cases have been registered since 2007 [11]. In 
Finland, children with suspected active TB are admit-
ted for investigations to a public hospital. The Finnish 
Care Register for Health Care (Hilmo) has registered 
all public hospitalisations since 1994 with more than 
95% coverage [16]. Each visit is classified according 
to the International Classification of Diseases (ICD)-9 
(1987–1995) or ICD-10 (1996–present) [16]. The Finnish 
Population Information System administrated by the 
Population Register Centre contains the basic informa-
tion of residents in Finland. Personal identity codes 
allow identification of each individual and linkage 
of data from the NIDR, Hilmo, the Finnish Population 
Information System and medical patient records.
The data collection flowchart is presented in Figure 1. 
TB patients under the age of 16 years were identified 
from the NIDR (accessed 30 June 2016), and patients 
younger than 16 years with an ICD-9 (010–018) or ICD-
10 (A15–19) diagnostic code for TB were identified from 
the Hilmo (accessed 17 November 2016). We requested 
the medical patient records of all identified TB patients 
from the relevant hospitals, verified the TB diagnosis 
and collected clinical data. We considered cases to be 
incident at the time of their first consultation for symp-
toms or of referral that led to the diagnosis, and patients 
under 15 years of age were classified as paediatric TB 
cases and included in the data analysis. The patients 
or their families were not contacted. A case of active TB 
was defined as a person diagnosed and started on a 
full course of TB treatment with or without bacteriologi-
cal or histological confirmation. We excluded patients 
whose treatment was discontinued because the diag-
nosis changed to other than active TB, who were ini-
tially diagnosed abroad or whose medical records were 
not available. The National Vaccination Register (NVR) 
does not include BCG data from the study period. The 
BCG status was classified from the medical records as 
vaccinated, non-vaccinated or unknown. The patients’ 
and parents’ country of birth were obtained from the 
Population Register Centre. The annual number of TB 
cases older than 15 years for the overall TB incidence 
trend was obtained from the open access NIDR data-
base (accessed 18 Oct 2018) [17]. Demographic data 
of the birth cohorts and population was obtained from 
the Statistics Finland population database (accessed 
18 Oct 2018) [18].
Cases were defined as bacteriologically confirmed or 
clinically diagnosed, pulmonary or extrapulmonary, 
and multidrug-resistant according to the WHO guide-
lines [1]. An index case was defined from the medical 
records and classified as a household contact if the 
child had lived in the same household at any time dur-
ing transmission. Patients were classified as native 
(born in Finland) or foreign-born. Native cases were 
further classified as second-generation migrants if 
at least one parent had been born abroad. According 
to the national selective BCG guideline published by 
the THL, the children were classified to be eligible for 
BCG if the child or at least one parent had been born 
in a country with high TB incidence, classified as inci-
dence of at least 50 per 100,000 population [19].
Statistics
For comparison of descriptive data between the native 
and foreign-born TB cases, we used a Mann–Whitney U 
and two-tailed Fisher’s exact or chi-squared test 
for the analysis of continuous and categorical data, 
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Table 1
Demographic and clinical characteristics of children under 15 years of age with newly diagnosed active tuberculosis, 
Finland, 1995–2015 (n = 139)
All Native Foreign-born
p value
n % n % n %
Tuberculosis cases 139 100 50 36.0 89 64.0 NA
Second-generation migrant 24 17.3 24 48.0 NA NA NA
BCG-eligiblea 109 78.4 23 46.0 86 96.6   < 0.0001
Sex, male 72 51.8 25 50.0 47 52.8 0.75
Country of birthb
Somalia 59 42.4 7 14.0 52 58.4
NA
Ethiopia 10 7.2 4 8.0 6 6.7
Thailand 5 3.6 3 6.0 2 2.2
Afghanistan 6 4.3 1 2.0 5 5.6
Other 33 23.4 9 18.0 24 27.0
Age in years
Median 9.3 3.7 11.4
  < 0.0001
IQR 4.1–12.6 1.7–8.4 7.1–13.5
< 5 40 28.8 28 56.0 12 13.5
  < 0.0001
5–14 99 71.2 22 44.0 77 86.5
BCG
Yes 49 35.3 19 38.0 30 33.7
0.08c
No 27 19.4 5 10.0 22 24.7
Unknown 63 45.3 26 52.0 37 41.6 0.24
Case finding
Symptoms 67 48.2 21 42.0 46 51.7
0.002d
Contact investigation 48 34.5 29 58.0 19 21.3
TB screening 24 17.3 NA NA 24 27.0 NA
Index case
Household contact 45 32.4 19 38.0 26 29.2
0.0005c
Other 19 13.7 17 34.0 2 2.2
Unknown 75 54.0 14 28.0 61 68.5   < 0.0001
Clinical characteristics
pTB 75 54.0 31 62.0 44 49.4 0.42e
Smear-positive pTBg 8 10.7 3 9.7 5 11.4 0.99
Bacteriologically confirmed 63 45.3 16 32.0 47 52.8 0.15f
MDR-TB 1 0.7 0 0 1 1.1 0.99
BCG: Bacillus Calmette–Guérin; IQR: interquartile range; MDR: multidrug-resistant; NA: not applicable; pTB: pulmonary tuberculosis; TB: 
tuberculosis.
a Patient or parent(s) born in a high-TB incidence country (≥ 50/100,000 population).
 b Birth country of the child if foreign-born (n = 89) or of the parent(s) if second-generation migrant (n = 24). Native children with Finnish born 
parents (n = 26) not shown.
c Unknown excluded from the analysis.
d TB screening excluded from the analysis.
e Adjusted for age.
f Adjusted for age and infection focus (pulmonary or non-pulmonary).
g Denominator: patients for whom at least one respiratory smear sample obtained.
Bold numbers indicate statistical significance at p < 0.05. Percentages represent row or column percentages.
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respectively. We used a logistic regression model and 
its predictive margins to calculate proportions of pTB 
and bacteriologically confirmed TB adjusted for age 
and/or for site of infection. We calculated the inci-
dence rate of TB in children under 5 years of age per 
100,000 person-years in the birth cohorts with univer-
sal (1995 to August 2006) and selective vaccination 
(September 2006 to 2015) and used a Poisson log-
linear model to estimate the incidence rate ratio (IRR) 
between the birth cohorts. We assessed if there was 
overdispersion with respect to the Poisson model from 
residual deviance divided by degrees of freedom or 
using the likelihood ratio test, and assessed if nega-
tive binomial regression was needed. We calculated 
the annual TB incidence rate for all ages, all children 
under 15-years, native children under 15-years, foreign-
born children under 15-years and foreign-born children 
under 15-years from high-TB incidence countries, and 
analysed incidence trends in these populations with a 
negative binomial model with year as the sole explan-
atory variable. The specific codes for the models are 
available from the authors. A p value < 0.05 was consid-
ered statistically significant. Data were analysed with 
SPSS Statistics (Version 24, IBM Corporation, Armonk, 
United States (US)) and Stata15.1 (StataCorp LLC, TX, 
US).
Ethical statement
The procedures described here were carried out in 
accordance with the ethical standards described in 
the Helsinki Declaration revised in 2013. The eth-
ics approval for the study was given by the Research 
Ethical Committee of the THL (THL/1306/5.05.00/2016).
Results
We identified a total of 139 paediatric TB cases (Figure 
1). A total of 67 cases were diagnosed in 2007 to 2015 
of whom 11 (16.4%) were only registered in the Hilmo.
The detailed demographics and characteristics of the 
patients are presented in  Table 1. Eligibility for BCG 
vaccination could be determined conclusively for 138 
(99.3%) of the 139 cases; one case born in a low-TB 
incidence country to a mother from a low-TB incidence 
country without paternal data was classified as ineli-
gible for BCG. Among the 18 native TB cases born dur-
ing selective BCG policy, seven were eligible for BCG 
of whom five were BCG-vaccinated and two had an 
unknown BCG status. The index case was identified in 
64 (46.0%) of the 139 cases. Among the 27 native cases 
with parents born in a low-TB incidence country, the 
index case was identified in 21 and a household con-
tact in 11. There was one death due to TB (1/139; 0.7%): 
an infant born in Finland during the selective BCG pol-
icy with native-born parents and not BCG-vaccinated.
The demographics of the population in Finland and 
annual incidence of TB in the period 1995 to 2015 are 
listed in the Supplementary Table S1. The TB incidence 
rate trends from 1995 to 2015 are presented in Figure 2. 
During this period, the overall TB rate in Finland showed 
a decreasing trend (IRR = 0.95; 95% CI: 0.95–0.96). The 
TB rate among children under the age of 15 years – all 
vs foreign-born vs foreign-born from high-TB incidence 
countries – did not change significantly (IRR = 1.02; 
95% CI: 0.99–1.06 vs IRR = 0.98; 95% CI: 0.94–1.02 
vs IRR = 0.98; 95% CI: 0.94–1.02). The TB rate among 
native children younger than 15 years showed a slightly 
increasing trend with a relative annual increase of 6% 
(IRR = 1.06; 95% CI: 1.01–1.11).
In the period 1995 to 2015, a total of 1,227,221 chil-
dren were born in Finland. The country of birth of the 
mother was available for 99.8%. The 1995 to 2015 
birth cohorts and the number of TB cases in each birth 
cohort are detailed in  Table 2. The cohorts born dur-
ing the universal and the selective BCG period com-
prised, respectively, 678,221 children observed for 
3,391,105 person-years and 549,000 children observed 
for 2,030,509 person-years. The IRR of TB in children 
younger than 5 years in the selective-BCG cohorts com-
pared with the universal-BCG cohorts was 1.3 (95% CI: 
0.7–2.3; p = 0.47). There were two cases of severe TB: 
one born in 2004 during universal BCG policy and one 
born in 2009 during the selective BCG policy.
Discussion
Nine years into the selective BCG policy in Finland, the 
incidence of TB or severe TB in native children under 
the age of 5 years has not increased. The first years of 
life are the most critical without the protection of BCG: 
young children are vulnerable to severe TB and benefit 
from BCG immunisations the most [2,4]. A transient 
increase in TB and severe disease in those younger 
than 5 years has previously been reported from Sweden 
and the Czech Republic after a shift from universal to 
selective BCG vaccinations [9,10]. In France, univer-
sal BCG vaccinations were discontinued in 2007, with 
seemingly very little impact on the incidence of paedi-
atric TB or TB meningitis [20,21]. Multiple factors might 
explain why also in Finland, TB morbidity at age under 
5 years did not increase: the TB incidence in the gen-
eral population at the time of the BCG policy change 
was lower and the TB burden was concentrated to the 
indigenous older population [12]. Capturing the target 
group for selective vaccinations is also decisive yet 
unpredictable [8,9,22]. In Finland, the implementation 
of selective vaccinations was planned meticulously 
and BCG eligibility is determined in advance at public 
maternity clinics with very high attendance [12]. Thus, 
the immediate coverage of the target population was 
probably high. Nevertheless, as adult TB remains une-
radicated, TB exposure and infections among young 
children are inevitable. With the majority of the infant 
population not BCG-vaccinated, identifying TB-infected 
young children quickly through other TB control meas-
ures becomes increasingly imperative.
While the overall TB rate in Finland continues to 
decline, the incidence of TB in the population younger 
than 15 years is not decreasing. In fact, the incidence 
of TB in the native population younger than 15 years, 
including children born during both BCG policy periods, 
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Figure 2
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showed a slightly increasing trend. Simultaneously, the 
demographics in Finland have changed considerably. 
It is likely that the observed trends reflect an increas-
ing proportion of children under 15 years with second-
generation migrant background and a higher TB risk 
than those with Finnish-born parents; this is further 
demonstrated by the sudden increase in asylum seek-
ers and subsequent migrant TB cases in 2015 [23]. The 
TB incidence under 15 years in Finland was expected 
to increase slightly following the BCG policy revision 
[13,24]. Evaluation of the impact of the decreased BCG 
coverage on TB morbidity in that age group is possible 
when the selective BCG cohorts grow older.
Paediatric TB morbidity in Finland parallels the status 
in other parts of northwestern Europe: it is concen-
trated to families with an migrant background from 
TB-endemic countries [9,25,26]. The index of a non-
native case was frequently unknown, suggesting that 
foreign-born children are either exposed to TB abroad 
before arriving in Finland or their index cases in Finland 
remain unidentified. Furthermore, most foreign-born 
children were diagnosed through symptoms and less 
than a third through migrant TB screening, suggest-
ing that TB screening and/or contact investigations 
seem to miss foreign-born children with TB infections. 
The usual presentation was pTB; extrapulmonary dis-
ease was more common among foreign-born children 
but the difference was insignificant after adjusting for 
age. Approximately 11% of pTB cases were smear-pos-
itive, suggesting a low transmission risk of paediatric 
TB. Clinical diagnoses were common, highlighting the 
shortcomings of the current diagnostic techniques for 
paediatric TB. The proportion confirmed bacteriologi-
cally was higher among foreign-born children but the 
difference was insignificant after adjusting for age and 
site of infection. Our smear-positive rate compares well 
with previous studies [27]. The proportions of pTB and 
bacteriologically confirmed TB show a similar tendency 
as recent study from the United Kingdom (UK): young 
children are more likely to have pTB, and bacteriologi-
cal confirmation is less likely among young, native TB 
cases [25].
Selective BCG vaccinations depend strongly on the 
identification and capture of children with higher risk 
of TB exposure. In Finland, the estimated TB reduc-
tion with BCG immunisations of risk groups with a TB 
incidence ≥ 23.7/100,000 is close to that achieved with 
universal BCG [13]. The TB rate among the migrant pop-
ulation under 15 years from high-TB incidence coun-
tries was well above this threshold. Furthermore, 23 
of the 50 native-born TB cases had a parent(s) born 
in a country with high TB incidence, suggesting that 
a higher TB exposure risk passes to the second gen-
eration. Many native cases, however, had no evident 
parental TB exposure risk and yet had an index case 
within the household. In Finland, the older indigenous 
population (e.g. grandparents) remains a major reser-
voir for TB reactivation; they contracted TB infections 
when TB was endemic in their youth and still account 
for the majority of all TB cases [11,15]. This is likely to 
cause transmission risk directly to the grandchildren or 
indirectly through the parents. Inevitably, some high-
risk children who would have been captured with uni-
versal BCG vaccination will remain unvaccinated under 
the selective policy. BCG status was unknown for most 
native TB cases, although most had been born during 
the universal policy and were likely to be vaccinated. 
We did not identify any BCG-eligible native TB cases 
born during the selective policy who were unvacci-
nated, although two had an unknown BCG status. In 
the future, the NVR can further clarify the capture and 
weaknesses of our current selective vaccinations.
Accurate paediatric TB surveillance data are essential 
for evaluating the success of BCG policy. The NIDR is 
the only source for national TB data reported in Finland 
and in 2007, the estimated under-reporting was 5% 
[28]. Overall, the NIDR was missing 32% of paediatric 
TB cases: most were clinically diagnosed before 2007 
and probably missing because of the former strict 
register criteria. However, the NIDR was also missing 
11 of the 67 paediatric TB cases diagnosed between 
2007 and 2015. Evidently, relying on notifications from 
physicians can cause a major gap in case detection 
resulting in under-reporting of paediatric TB morbidity. 
Undernotification of paediatric TB from high-burden 
countries has become increasingly acknowledged [29]. 
However, statutory notifications are considered a good 
proxy indication of the true incidence in most of Europe 
[1]. Our findings compare well with the UK where an 
estimated 20% of paediatric cases were missing from 
the national surveillance system [30]. Although pub-
lished figures on TB under-reporting in Europe gen-
erally lack estimates specifically for the paediatric 
population, data suggest that culture- or smear-neg-
ative TB cases are more likely to remain unnotified 
[31,32]. Since achieving bacteriological confirmation in 
children is challenging, it is likely that compared with 
adults, paediatric TB cases are more often unnotified 
across Europe [2,31,32]. The World Health Organization 
adjustment factor accounting for under-reporting is 
standard for most European TB surveillance data [1]. 
Separate adjustment factors would probably increase 
the reliability of the estimates and, therefore, further 
inventory studies focusing on paediatric TB in Europe 
should be encouraged.
Our study had some limitations and the results should 
be interpreted with caution. All TB cases might not 
be captured, and the number of cases was small. 
Comprehensive BCG coverage of the patients or birth 
cohorts was not available. Index cases were based on 
the epidemiological link rather than molecular epide-
miology. Although we did not observe an increasing 
trend for the TB rate in native children younger than 
5 years, minor changes might be concealed under the 





We portray a rare view into paediatric TB epidemiology: 
a nationwide study looking at a 21-year period includ-
ing a transition into a low-incidence country along 
with a major demographic shift and fundamental revi-
sion of the BCG policy. A major strength of our study 
is the capture of paediatric TB cases from separate 
nationwide registers, with all cases confirmed from the 
medical patient records. The paediatric TB morbidity 
in Finland is concentrated in families with an migrant 
background from TB endemic countries. The TB mor-
bidity in native children younger than 5 years in Finland 
did not increase after the BCG policy revision, suggest-
ing that well implemented selective vaccinations can 
prevent TB in the most vulnerable age group nearly as 
effectively as universal vaccinations in low-incidence 
settings. Even in a high-income country with statutory 
notifications, the national TB surveillance registry can 
miss a substantial number of paediatric TB cases. 
Implementing separate adjustment factors for paediat-
ric TB notifications could increase the reliability of TB 
surveillance data.
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Table 2
Birth cohorts born during universal or selective BCG vaccination policy and incidence of active tuberculosis in those 
younger than 5 years, per 100,000 person-years in each cohort, Finland, 1995–2015 (n = 42)






TB cases (severec) Total incidence ratee
n % n % Total With a high-risk parentd Incidence 95% CI
Universal BCG policy
1995 63,067 1,881 3.0 1,179 1.9 315,335 4 2 1.3 0.3–3.2
1996 60,723 1,989 3.3 1,248 2.1 303,615 4 4 1.3 0.4–3.4
1997 59,329 2,133 3.6 1,371 2.3 296,645 1 1 0.3 0.01–1.9
1998 57,108 2,267 4.0 1,439 2.5 285,540 0 0 0.0 0.0–1.3
1999 57,574 2,382 4.1 1,536 2.7 287,870 2 2 0.7 0.1–2.5
2000 56,742 2,381 4.2 1,560 2.7 283,710 3 1 1.1 0.2–3.1
2001 56,189 2,633 4.7 1,700 3.0 280,945 2 0 0.7 0.1–2.6
2002 55,555 2,696 4.9 1,777 3.2 277,775 0 0 0.0 0.0–1.3
2003 56,630 2,825 5.0 1,883 3.3 283,150 3 1 1.1 0.2–3.1
2004 57,758 2,959 5.1 1,942 3.4 288,790 2 (1) 2 (1) 0.7 0.1–2.5
2005 57,745 3,220 5.6 2,104 3.6 288,725 1 0 0.3 0.01–1.9
I/2006f 39,801 2,378 6.0 NA NA 199,005 2 1 1.0 0.1–3.6
Selective BCG policy
II/2006g 19,039 1,138 6.0 NA NA 95,195 2 1 2.1 0.3–7.6
2007 58,729 3,690 6.3 2,417 4.1 293,645 3 0 1.0 0.2–3.0
2008 59,530 3,923 6.6 2,614 4.4 297,650 4 2 1.3 0.4–3.4
2009 60,430 4,290 7.1 2,806 4.6 302,150 2 (1) 1 (0) 0.7 0.1–2.4
2010 60,980 4,760 7.8 3,071 5.0 304,900 1 0 0.3 0.01–1.8
2011 59,961 4,969 8.3 3,300 5.5 269,825 2 0 0.7 0.1–2.7
2012 59,493 5,415 9.1 3,594 6.0 208,226 1 0 0.5 0.01–2.7
2013 58,134 5,625 9.7 3,691 6.3 145,335 1 1 0.7 0.02–3.8
2014 57,232 6,219 10.9 4,069 7.1 85,848 2 2 2.3 0.3–8.4
2015 55,472 6,363 11.5 4,195 7.6 27,736 0 0 0.0 0.0–13.3
BCG: Bacillus Calmette–Guérin; CI: confidence interval; NA: not available; TB: tuberculosis.
a Mother born in a high-TB incidence country (≥ 50/100,000 population).
b Total person-years in cohort observed until 31 December 2015 or in those 5 years of age.
c Meningeal or miliary.
d At least one parent born in a high-TB incidence country (≥ 50/100,000 population).
e Number of cases per 100,000 person-years.
f Born from January to August 2006.
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